Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2261
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure ; volume:21 ; number:1 ; day:21 ; month:7 ; year:2021 ; pages:1-8 ; date:12.2021
BMC cardiovascular disorders ; 21, Heft 1 (21.7.2021), 1-8, 12.2021
- Urheber
-
Nakagaito, Masaki
Imamura, Teruhiko
Joho, Shuji
Ushijima, Ryuichi
Nakamura, Makiko
Kinugawa, Koichiro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12872-021-02163-7
- URN
-
urn:nbn:de:101:1-2021102302091038204889
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nakagaito, Masaki
- Imamura, Teruhiko
- Joho, Shuji
- Ushijima, Ryuichi
- Nakamura, Makiko
- Kinugawa, Koichiro
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Iatrogenic Decompensated Heart Failure
Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Iatrogenic Decompensated Heart Failure
Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
Iatrogenic Decompensated Heart Failure
Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure